rs1205454520
|
|
|
0.030 |
GeneticVariation |
BEFREE |
KRAS mutations were detected in 4 (3%) of 117 tumors (3× G12D and 1 G12V mutation).One tumor had a PIK3CA E545K mutation.
|
23158210 |
2013 |
rs1205454520
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Furthermore, enhancement of TLX activity, by either ectopic expression or ligand stimulation, could potently prevent doxorubicin-induced senescence in prostate cancer cells and also allow prostatic epithelial cells to escape oncogene-induced senescence induced either by activated oncogene H-Ras(G12V) or knockdown of tumour suppressor PTEN, via a mechanism of direct but differential transcriptional regulation of two senescence-associated genes, repression of CDKN1A and transactivation of SIRT1.
|
25557355 |
2015 |
rs1205454520
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Each of three Ki-ras(G12V) transfectants responded to TGF-beta1 by an increase in proliferation and by decreasing the abundance of the Cdk inhibitor p21 and the tumor suppressor PTEN, whereas each of three wild-type Ki-ras transfectants remained unresponsive to TGF-beta1.
|
11029459 |
2001 |
rs1029342144
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Statistically significant associations were noted between SNPs in beta-catenin and APOE and a positive family history of cancer (beta-catenin: p=0.034, APOE: p=0.033); tumor location and a DCC SNP (p=0.038) and the P53 R72P mutation and survival (p=0.0336).
|
15523694 |
2005 |
rs1029342144
|
|
|
0.020 |
GeneticVariation |
BEFREE |
There was no evidence of such an effect on survival within the TP53-mutated tumor group for TP53 R72P carriers but a suggestion of an effect for MDM2 SNP309 carriers (GG vs. TT-genotype HR 2.99, P = 0.06).
|
21667122 |
2011 |
rs1114167628
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These results further demonstrated the functional consequences of breast cancer-derived nherf1 mutations (K172N and D301V), and suggested the causal role of NHERF1 in tumor development and progression.
|
24012959 |
2013 |
rs1197734477
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls.
|
28186998 |
2017 |
rs121909222
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results demonstrate that WAP-Cre:Pten(f/f):p53(lox.stop.lox_R270H) mice represent a tractable model to study basal-like breast cancer because unlike p53 deletion, p53(R270H) mutation in the mouse does not skew tumors toward the claudin-low subtype.
|
26781438 |
2016 |
rs121909224
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We used whole exome sequencing to examine the mutation profiles of the LMD tumor DNA in CSF before therapeutic response and after disease relapse, and discovered a canonical cancer mutation PTEN (R130*) at both time points.
|
26961773 |
2016 |
rs121909231
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Sequencing of the tumor showed homozygosity for c.1003C>T, confirming the presence of a germline mutation and implying loss of the second allele.
|
25756585 |
2015 |
rs121909235
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The mutation was identified in a patient with a glioma, and turned out to be a heterozygous germline mutation of PTEN (Arg234Gln), without loss of heterozygosity in tumour DNA.
|
12085208 |
2002 |
rs121909237
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Other mutations included: 1/78 (1.3%) successfully amplified tumor samples with TERT<sup> C228T</sup>; 2/79 (2.5%) NRAS 61 (c.181C>A and c.182A>G); 1/73 (1.4%) PIK3CA exon 9 (c.1589A>G and c.1598C>T in one tumor); 1/79 (1.3%) PIK3CA exon 20 (c.2951G>A); and 1/74 (1.4%) PTEN exon 5 (c.295G>A).
|
27824297 |
2017 |
rs121913294
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Molecular analysis suggest that tumors from double myrAKT;p53(R172H) mice result from acceleration of initiated p53(R172H) tumors and not from bypass of AKT-induced oncogenic senescence.
|
20174572 |
2010 |
rs398123316
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Other mutations included: 1/78 (1.3%) successfully amplified tumor samples with TERT<sup> C228T</sup>; 2/79 (2.5%) NRAS 61 (c.181C>A and c.182A>G); 1/73 (1.4%) PIK3CA exon 9 (c.1589A>G and c.1598C>T in one tumor); 1/79 (1.3%) PIK3CA exon 20 (c.2951G>A); and 1/74 (1.4%) PTEN exon 5 (c.295G>A).
|
27824297 |
2017 |
rs765433422
|
|
|
0.010 |
GeneticVariation |
BEFREE |
KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C).
|
29409955 |
2018 |
rs868257011
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These results further demonstrated the functional consequences of breast cancer-derived nherf1 mutations (K172N and D301V), and suggested the causal role of NHERF1 in tumor development and progression.
|
24012959 |
2013 |
rs878853941
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mutation analysis of the entire coding region of PTEN including splice sites was performed in 33 tumors, revealing one tumor with somatic L182F (exon 6).
|
11021813 |
2000 |
rs886041332
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Introducing the PDK1(K465E/K465E) PH domain knock-in mutation into cancer-prone PTEN(+/-) mice, lowered Akt activity only by about 50%, but led to a delay in tumour onset of ∼4 months in a broad range of tumours.
|
20959631 |
2011 |
rs121909229
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |